堃博医疗-B涨近10%，BroncTarget进入创新医疗器械特别审查通道

Core Viewpoint - Kintor Pharmaceutical-B (2216.HK) experienced a nearly 10% increase in stock price, reaching HKD 2.65, with a total market capitalization of HKD 1.395 billion, following the announcement of its BroncTarget® system entering the special review process by the National Medical Products Administration of China [1][2]. Group 1 - The BroncTarget® system is a breakthrough interventional technology aimed at treating moderate to severe chronic obstructive pulmonary disease (COPD), designed to alleviate symptoms such as cough, sputum production, and breathing difficulties [1]. - The product has received recognition from the regulatory authority for its originality in core technology and significant clinical value [1]. - Confirmatory clinical trials for the BroncTarget® system are currently underway, with participant recruitment being conducted across 28 hospitals nationwide [1]. Group 2 - The stock price of Kintor Pharmaceutical-B rose by 9.96%, with a trading volume of 1.271 million shares and a total transaction value of HKD 3.2929 million on January 13 [2]. - The stock reached a high of HKD 2.70 and a low of HKD 2.43 during the trading session, with an average price of HKD 2.59 [2]. - The company has a total share capital of 527 million shares, with a market-to-book ratio of 1.108 [2].